Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gottlieb Floats New Antibiotic Payment Model In LPAD Announcement

Executive Summary

US FDA Commissioner outlines licensing fee reimbursement arrangement intended to provide better financial incentives for development.


Related Content

Non-Traditional Antimicrobials Can Follow Regulatory Path Laid By Small Molecule Antibiotics, US FDA Says
Alarm As Novartis Exits Antibiotics Space
BARDA Official Worries About How Non-Traditional Antibiotics Will Get To Market
Antibiotic Development Question: Should A Phage Library Equal One Application?
Biosimilars Need Better Reimbursement, Not 'Kabuki' Coverage, Gottlieb Tells Insurers
Best Of BIO: Policy & Regulatory Updates From BIO 2017
Gottlieb's Confirmation: Will Industry Ties Remain A Big Deal After The Hearing?
FDA Worries About Off-Label Use, Stewardship With Limited-Population Approval Pathway





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts